MVT-602

MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism.[1][2] It has been found to increase luteinizing hormone levels in premenopausal women.[2] As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism.[1] It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.[1]

MVT-602
Clinical data
Other namesRVT-602; TAK-448
Identifiers
IUPAC name
  • (2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide
    or
    Ac-D-Tyr-Hyp-Asn-Thr-Phe-Unk-Leu-Arg(Me)-Trp-NH2
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
ChEMBL
Chemical and physical data
FormulaC58H80N16O14
Molar mass1225.376 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=NC)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4C[C@H](CN4C(=O)[C@@H](CC5=CC=C(C=C5)O)NC(=O)C)O)O
InChI
  • InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1
  • Key:MWXWMWSUUYXMRA-GRKBUMBKSA-N

References

  1. "MVT 602". Adis Insight. Springer Nature Switzerland AG.
  2. Abbara A, Eng PC, Phylactou M, Clarke SA, Richardson R, Sykes CM, et al. (December 2020). "Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders". The Journal of Clinical Investigation. 130 (12): 6739–6753. doi:10.1172/JCI139681. PMC 7685751. PMID 33196464.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.